|
Age at date of HTx (years)
|
49.4 ± 12.6
|
49.4 ± 12.6
|
49.4 ± 13.3
|
0.98
|
|
Gender (men/women)
|
86 (83 %)/18 (17 %)
|
65 (82 %)/14 (18 %)
|
21 (84 %)/4 (16 %)
|
0.46
|
|
BMI
|
25.8 ± 3.3
|
25.9 ± 3.5
|
25.3 ± 2.8
|
0.51
|
|
Reason for HTx
| | | | |
|
CAD
|
50 (48 %)
|
37 (47 %)
|
13 (52 %)
|
0.68
|
|
Dilated cardiomyopathy
|
44 (42 %)
|
35 (44 %)
|
9 (36 %)
|
0.07
|
|
Others
|
10 (10 %)
|
7 (9 %)
|
3 (12 %)
|
0.14
|
|
Systemic hypertension
|
88 (85 %)
|
65 (82 %)
|
23 (92 %)
|
0.78
|
|
Diabetes mellitus
|
18 (17 %)
|
14 (18 %)
|
4 (16 %)
|
0.68
|
|
Hypercholesterolemia
|
76 (73 %)
|
58 (73 %)
|
18 (72 %)
|
0.25
|
|
Renal failure
|
71 (68 %)
|
51 (65 %)
|
20 (80 %)
|
0.22
|
|
Malignancy
|
14 (13 %)
|
13 (16 %)
|
1 (4 %)
|
0.12
|
|
Peripheral artery disease
|
12 (12 %)
|
10 (13 %)
|
2 (8 %)
|
0.55
|
|
Beta blockers
|
26 (25 %)
|
19 (24 %)
|
7 (28 %)
|
0.55
|
|
Calcium channel antagonists
|
88 (85 %)
|
72 (91 %)
|
16 (64 %)
|
0.04
|
|
ACE inhibitors
|
27 (26 %)
|
19 (24 %)
|
8 (32 %)
|
0.39
|
|
Statins
|
94 (90 %)
|
73 (92 %)
|
21 (84 %)
|
0.77
|
|
Coronary interventions in the follow-up
|
15 (15 %)
|
13 (16 %)
|
2 (8 %)
|
0.06
|
|
MACE (incl. interventions)
|
20 (19 %)
|
15 (19 %)
|
5 (20 %)
|
0.14
|
|
Deaths in observation period
|
11 (11 %)
|
7 (9 %)
|
4 (16 %)
|
0.26
|
